Clinical specialities

#Animal models #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Therapeutics #Toxicology

ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need

ADCs and solid tumours - The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 - Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types… Read More

#Exclusive Content

#Assay development optimisation & technology #Clinical specialities #High Content Screening #Immunology #PCR #RNA

Sino Biological partners with Nanommune to develop coronavirus multiplex serological assay

Sino Biologica has announced a co-development agreement with Nanommune, an Irvine, California-based biotechnology company specialising in the development and application of multiplex array technology. Under the terms of the agreement, the two companies will jointly develop coronavirus antigen array products for serological studies of COVID-19 and other infectious… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Oncology #PCR #Precision medicine #Regulatory #RNA #Therapeutics #Translational #Translational chemistry

Antimicrobial resistance threatens to undermine our healthcare system

Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 - Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. While antimicrobial resistance (AMR) does… Read More

#Exclusive Content

#Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Genetics / genomics #Imaging #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pathology #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry

Innovative glycan imaging methods drive cancer biomarker discovery

Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 - Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role in disease… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Reprogramming the stem cell for a new generation of cures

Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Preclinical #RNA #System biology #Systems biology #Therapeutics

Drug development 2.0 – The partnership model in practice

Drug development 2.0 - The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #PCR #Preclinical #RNA #Therapeutics

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules or biologics becomes increasingly… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Harnessing the modified proteome for increased diagnostic power

Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

2030 Life Sciences and Health in the Digital Age (Part 2)

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Oncology #Regulatory #Screening #Sequencing #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal... driving stronger biomarker-based insights and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Microbiome #Oncology #Pharmokinetics #Preclinical #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Microbiology #Nanomedicine / nanotechnology #Organic chemistry #Pathology #Precision medicine #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

2030 Life Sciences and Health in the Digital Age (Part 1)

2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to look ahead, to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell culture #Cellular & Molecular biology #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Precision medicine #RNA #Sequencing

Why precision medicine must address genetic diversity

From human genome to global genome - why precision medicine must address genetic diversity By Sumit Jamuar, et al. The publication of the first human genome sequence more than 15 years ago marked the start of a new era in medicine. In the years since then, researchers have greatly expanded… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Precision medicine #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Application of bioinformatics in support of precision medicine

Application of bioinformatics in support of precision medicine By Mike Furness and John Wise Bioinformatics has played a major role in gene sequencing diagnostics and has been an essential tool to investigate the genetic causes of disease. With the support of new technologies and tools, bioinformatics can play an important… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene editing #Gene therapy #Genomics #Lead discovery #Oncology #Pharmacology #Regenerative Medicine #Regulatory #Screening #Stem cells #System biology #Systems biology #Therapeutics

Cell Therapy – Falling short of its potential?

Cell Therapy - Falling short of its potential? By Pierre-Louis Joffrin Despite major investment in the field, few cell therapies have gained regulatory approval with limited commercial success. The success of therapeutic products is defined by three factors: safety, efficacy and scalability. Achieving these for cell therapy presents new challenges;… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #High Content Screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Pharmacology #Precision medicine #Preclinical #QA/QC #Regulatory #RNA #System biology #Systems biology #Toxicology #Translational #Translational chemistry

The Reality of Virtual Pharmaceutical Companies

The Reality of Virtual Pharmaceutical Companies By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr We discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous task. The vagaries… Read More

#Archive